《美股業績》化工股杜邦(DD.US)季度轉虧 中國銷售跌14%
美國化工企業杜邦(DuPont de Nemours)(DD.US)公布第二季度業績。季度股東應佔虧損1.31億美元,對上年度純利7.87億美元。每股季度攤薄虧損28美仙,經調整後為每股純利85美仙,高於市場預期的83美仙。季度淨銷售按年跌7%至30.94億美元,期內中國銷售按年跌14%,受電子業需求疲弱影響。
公司上調全年銷售預測,由介乎123億至125億美元上調至介乎124.5億至125.5億美元,市場預期為124.4億美元。公司5月曾把全年銷售預測上限由129億美元下調至125億美元。第三季度經調整每股盈利預測為84美仙,差於市場預期的93美仙。
該股昨日(2日)跌0.9%,報76.38美元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.